Law Office of Brodsky & Smith, LLC Announces Investigation of Amylin Pharmaceuticals, Inc.
07 Luglio 2012 - 3:00PM
Business Wire
Law office of Brodsky & Smith, LLC announces that it is
investigating potential claims against the Board of Directors of
Amylin Pharmaceuticals, Inc (“Amylin” or the “Company”) (Nasdaq-
AMLN) relating to the proposed acquisition by Bristol-Myers Squibb
Company. (“Bristol-Myers”).
Under the terms of the transaction, Amylin shareholders will
receive only $31.00 in cash for each of Amylin stock they own. The
investigation concerns possible breaches of fiduciary duty and
other violations of state law by the Board of Directors of Amylin
for not acting in the Company’s shareholders' best interests in
connection with the sale process to Bristol-Myers. The Board of
Directors may have failed to adequately shop the Company and may
have undervalued Amylin resulting in harm to the Amylin
shareholders. For example, an analyst has placed a $32.00 price
target on Amylin stock.
If you own shares of Amylin stock and wish to discuss the legal
ramifications of the proposed transaction, or have any questions,
you may e-mail or call the law office of Brodsky & Smith, LLC
who will, without obligation or cost to you, attempt to answer your
questions. You may contact Jason L. Brodsky, Esquire or Evan J.
Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite
602, Bala Cynwyd, PA 19004, by e-mail at
investorrelations@brodsky-smith.com visiting
http://brodsky-smith.com/444-amln-amylin-pharmaceuticals-inc.html,
or by calling toll free 877-LEGAL-90.
Grafico Azioni Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Storico
Da Giu 2023 a Giu 2024
Notizie in Tempo Reale relative a Amylin Pharmaceuticals, Inc. (MM) (NASDAQ): 0 articoli recenti
Più Brodsky & Smith, LLC Articoli Notizie